Suppr超能文献

术中放疗与调强放疗治疗早期乳腺癌的成本效益分析:一项放弃投资分析。

Cost-effectiveness of intraoperative radiation therapy versus intensity-modulated radiation therapy for the treatment of early breast cancer: a disinvestment analysis.

机构信息

Health Technology Assessment Unit, Arturo Lopez Perez Foundation, Santiago, RM, Chile.

Radiotherapy Department, Arturo Lopez Perez Foundation, Santiago, RM, Chile.

出版信息

BMC Health Serv Res. 2024 Apr 3;24(1):417. doi: 10.1186/s12913-024-10739-0.

Abstract

BACKGROUND

Adjuvant radiotherapy represents a key component in curative-intent treatment for early-stage breast cancer patients. In recent years, two accelerated partial breast irradiation (APBI) techniques are preferred for this population in our organization: electron-based Intraoperative radiation therapy (IORT) and Linac-based External Beam Radiotherapy, particularly Intensity-modulated radiation therapy (IMRT). Recently published long-term follow-up data evaluating these technologies have motivated a health technology reassessment of IORT compared to IMRT.

METHODS

We developed a Markov model to simulate health-state transitions from a cohort of women with early-stage breast cancer, after lumpectomy and adjuvant APBI using either IORT or IMRT techniques. The cost-effectiveness from a private health provider perspective was assessed from a disinvestment point of view, using life-years (LYs) and recurrence-free life-years (RFLYs) as measure of benefits, along with their respective quality adjustments. Expected costs and benefits, and the incremental cost-effectiveness ratio (ICER) were reported. Finally, a sensitivity and scenario analyses were performed to evaluate the cost-effectiveness using lower IORT local recurrence and metastasis rates in IORT patients, and if equipment maintenance costs are removed.

RESULTS

IORT technology was dominated by IMRT in all cases (i.e., fewer benefits with greater costs). Despite small differences were found regarding benefits, especially for LYs, costs were considerably higher for IORT. For sensitivity analyses with lower recurrence and metastasis rates for IORT, and scenario analyses without equipment maintenance costs, IORT was still dominated by IMRT.

CONCLUSIONS

For this cohort of patients, IMRT was, at least, non-inferior to IORT in terms of expected benefits, with considerably lower costs. As a result, IORT disinvestment should be considered, favoring the use of IMRT in these patients.

摘要

背景

辅助放疗是早期乳腺癌患者治愈性治疗的关键组成部分。近年来,在我们的机构中,两种加速部分乳腺照射(APBI)技术被用于该人群:基于电子的术中放射治疗(IORT)和基于直线加速器的外部束放射治疗,特别是强度调制放射治疗(IMRT)。最近发表的评估这些技术的长期随访数据促使我们对 IORT 与 IMRT 进行了医疗技术再评估。

方法

我们开发了一个马尔可夫模型,以模拟接受保乳手术后接受辅助 APBI 的早期乳腺癌患者队列的健康状态转变。从私营医疗保健提供者的角度出发,从撤资的角度评估成本效益,使用生命年(LYs)和无复发生命年(RFLYs)作为收益的衡量标准,以及各自的质量调整。报告了预期成本和收益以及增量成本效益比(ICER)。最后,进行了敏感性和情景分析,以评估 IORT 患者局部复发和转移率较低的成本效益,以及是否可以免除设备维护成本。

结果

在所有情况下,IORT 技术均被 IMRT 所主导(即,成本较高但收益较少)。尽管在收益方面存在较小差异,特别是在 LYs 方面,但 IORT 的成本要高得多。对于 IORT 局部复发和转移率较低的敏感性分析以及不包括设备维护成本的情景分析,IORT 仍被 IMRT 所主导。

结论

对于该患者队列,至少从预期收益的角度来看,IMRT 并不逊于 IORT,而且成本要低得多。因此,应考虑撤资 IORT,优先在这些患者中使用 IMRT。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1d6/10988977/b430aea8743f/12913_2024_10739_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验